Charles River to acquire Frontage's bioanalysis and DMPK operations for $470M cash
At a glance
- $CRL today−0.36%last $334.32
- Vs industry peers−0.29 pts6-peer median −0.06% · in step
- Since Nov 9−2.25%from the first trade after the story
- 52-week range11.9% below high$146.20 – $379.63
- Last reported profit$333.1Mquarter to Sep 26, 2026 · 10-Q
- In the headline$470 millionAmount
Nothing reported about charles river across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: $CRL's deal hinges on more than just the price — how it's paid, who's funding it, and if regulators greenlight the move could shape its future more than the headline suggests.
- How the stock is trading: $CRL -0.36% in the latest session.
- Timing: It came out pre-market, so the next session was the first that could react.
Where the stock stands
Charles River Laboratories Inte ($CRL) slipped 0.36% to $334.32 in the latest session. Over the past month it is up 11.4%. It now sits 12% under the 52-week high of $379.63 and 129% above the year's low of $146.20. It has been a volatile year: the high was 2.6 times the low, so moves this size are not unusual for it.
What the filings say
In its latest report (10-Q, filed Nov 4, 2026), $CRL earned $333.1M over the quarter to Sep 26, 2026 on revenue of $982.7M (-2.1% QoQ). Operations brought in $474.9M of cash over the nine months to Sep 26, 2026; after capital spending, free cash flow was $341.1M. Total liabilities were $4.18B against $200.4M of cash on Sep 26, 2026. The company filed an 8-K — the form for material events — on Nov 9, the same day as this story; it is $CRL's own account and the first thing to read. Figures are as filed with the SEC; the $CRL page has the full statements.
How much coverage it is getting
Wook has filed 2 stories on Charles River Laboratories Inte in the last 30 days, 0 of them this week. None came this week, so coverage has gone quiet. Going by their wording, 0 read bullish, 2 neutral and 0 bearish. This one reads neutral too, in line with most of them. 2 came from Seeking Alpha and the rest from other outlets, so more than one newsroom is on it.
The bigger picture
In healthcare, timing is everything — a single trial result or FDA decision can shift a drugmaker's fate, while broader policy shifts ripple across the entire industry. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
The $CRL page has all the charts, filings, and models to back up every number. Comparing coverage from different outlets is key to spotting confirmation or repetition. Wook AI can pull live data and run the numbers on request — like how far $CRL is from its peak or how this week's coverage stacks up.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Seeking Alpha published this on November 9, 2026. $CRL has moved -2.25% ($342.00 to $334.32). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
